ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.534,07
0,31%
S&P 500
6.061,48
0,39%
US Dollar vs BRL
5,8048
0,01%
Bitcoin
98.061,59
1,49%
Brent Oil
74,585
0,01%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. FibroGen Inc (FGEN)

  7. FibroGen Inc (FGEN) Notícias

FGEN

FibroGen (FGEN)

FibroGen Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:FGEN
DataHoraFonteTítuloCódigoCompanhia
10/01/202520:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
18/12/202419:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
16/12/202411:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FGENFibroGen Inc
16/12/202410:05GlobeNewswire Inc.FibroGen Appoints David DeLucia as Chief Financial OfficerNASDAQ:FGENFibroGen Inc
14/11/202418:52Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:FGENFibroGen Inc
12/11/202418:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FGENFibroGen Inc
12/11/202418:05GlobeNewswire Inc.FibroGen Reports Third Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
04/11/202418:05GlobeNewswire Inc.FibroGen to Report Third Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
03/09/202417:05GlobeNewswire Inc.FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:FGENFibroGen Inc
07/08/202418:10Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FGENFibroGen Inc
06/08/202417:05GlobeNewswire Inc.FibroGen Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:FGENFibroGen Inc
30/07/202417:07GlobeNewswire Inc.FibroGen to Report Second Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
30/07/202417:05GlobeNewswire Inc.FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate UpdateNASDAQ:FGENFibroGen Inc
11/07/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:FGENFibroGen Inc
18/06/202409:00GlobeNewswire Inc.FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024NASDAQ:FGENFibroGen Inc
03/06/202417:05GlobeNewswire Inc.FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical TrialsNASDAQ:FGENFibroGen Inc
03/06/202417:02GlobeNewswire Inc.FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid TumorsNASDAQ:FGENFibroGen Inc
03/06/202408:00GlobeNewswire Inc.FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:FGENFibroGen Inc
23/05/202418:05GlobeNewswire Inc.FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical OncologyNASDAQ:FGENFibroGen Inc
07/05/202412:55AllPennyStocks.comTraders Rush To Buy Biotech Following Q1 Earnings BeatNASDAQ:FGENFibroGen Inc
07/05/202408:00GlobeNewswire Inc.FibroGen to Participate in Upcoming Investor ConferencesNASDAQ:FGENFibroGen Inc
06/05/202417:02GlobeNewswire Inc.FibroGen Reports First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
29/04/202408:00GlobeNewswire Inc.FibroGen to Report First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
24/04/202417:02GlobeNewswire Inc.FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology ANASDAQ:FGENFibroGen Inc
02/04/202418:46GlobeNewswire Inc.FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:FGENFibroGen Inc
26/03/202408:00GlobeNewswire Inc.FibroGen to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:FGENFibroGen Inc
11/03/202408:00GlobeNewswire Inc.FibroGen Appoints Deyaa Adib, M.D. as Chief Medical OfficerNASDAQ:FGENFibroGen Inc
26/02/202418:06GlobeNewswire Inc.FibroGen Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
26/02/202418:05GlobeNewswire Inc.FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South KoreaNASDAQ:FGENFibroGen Inc
20/02/202409:00GlobeNewswire Inc.FibroGen to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:FGEN

Seu Histórico Recente

BOV
PRIO3
PETRORIO ON
BOV
FICT3
Fictor Alimentos ON
BOV
RAIZ4
Raizen S.A PN
BOV
AMAR3
LOJAS MARISA ON
BOV
RNEW4
RENOVA PN
BOV
IBOV
Índice Bovespa
BOV
GFSA3
GAFISA ON
BOV
TEKA4
TEKA PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios